AIM and AyalaTBI Case Studies on Technology Entrepreneurship.pdf
Three case studies document the challenges and opportunities faced by entrepreneurs in the Philippines and abroad. The case studies, jointly owned by Ayala Foundation and the Asian Institute of Management serve as learning materials for start-up enterprises in science and technology:
“Jupiter Systems Case”
Abstract: Jupiter is a local enterprise software firm, with an installed base of more than 300 client companies in the mid-sized manufacturing and distribution markets in the Philippines and abroad. In the past 20 years, Jupiter had grown from a two-man development team to a 100-staff major player. However, operational constraints and market realities had severely affected Jupiter’s future. The CEO is deciding on the future paths of Jupiter in the areas of niched segments in vehicle dealership market, outsourced services, and improved branded software. Click here to launch the full story.
“The Tivoli Systems Story”
Abstract: Tivoli Systems was an Austin, Texas based company acquired by IBM in 1996 for $743m USD. Their main product was called middleware software, a type of software that allows system administrators to easily control and manage different types of computer hardware and software resources that are connected through a network. Tivoli Systems was co-founded by Peter Valdes, a Filipino who migrated to the U.S. to do his graduate studies. This case is an anatomy of how a tech startup was conceptualized and made operational, funded and eventually acquired by a big company in the United States. It shows a real world situation of how technopreneurs really make decisions, from the technology entrepreneur’s point of view. It also shows Mr. Valdes plans for a new startup, after his first successful one. Click here to launch the full story.
“The $741M Painkiller from Deadly Cone Snails”
Abstract: This case shows how conopeptides, which are toxins from deadly marine conesnails found in tropical countries like the Philippines, offer a new source of drugs from marine life. The first of these new class of drugs called conopeptides is Ziconotide. Ziconotide is a powerful painkiller that can block the chronic pain suffered by AIDS, cancer, and some types of patients who are not helped by morphine. It was approved by the US Food and Drug Administration in December 2004. Ziconotide was developed from a Philippine cone snail called Conus Magus. The company that developed Ziconotide, San Diego based biotech company Neurex, was acquired by Irish biotech firm Elan Pharmaceuticals for $741m in stock, just so it could acquire the intellectual property for Ziconotide. This case serves as an overview of some of the issues and challenges that need to be faced when developing a new drug. Click here to launch the full story.